Form D · Pharmaceuticals

Actinium Pharmaceuticals, Inc.

New York, NY · CIK 0001388320

Offering snapshot reported Jan 21, 2014 · SEC filing

Reported sold
$6.64M
Offering amount: $6.64M
Investors reported
63
Form D · investor count
Minimum accepted
$5K
Reported outside-investor minimum
First sale
Dec 27, 2013
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$3.32M$6.64MJan 7, 2014: $3,325,860.00Jan 7, 2014Jan 21, 2014: $6,636,720.00Jan 21, 2014

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$3,325,860 → $6,636,720
  • Reported investors36 → 63

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 21, 2014Amendment$6,636,720$3,310,860vs Jan 7, 201463SEC filing
Jan 7, 2014Initial$3,325,860No comparison36SEC filing
Oct 8, 2013Initial$0No comparison25SEC filing
Sep 4, 2013Initial$0No comparison13SEC filing
Mar 19, 2013Initial$0No comparison348SEC filing
Jan 14, 2013Initial$0No comparison60SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$664K
Finders' fees
$0
Form D file number
021-209458
Included in the sales commission amount is a 2% allowance for expenses paid to the agent. The agent also received warrants to purchase 138,265 shares of common stock of the issuer.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Recipient Laidlaw & Company (UK) Ltd.119037

Source: Form D, filed Jan 21, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Dragan Cicic Executive
Kaushik J. Dave Director, Executive
David Nicholson Director
Sandesh Seth Director
Richard I. Steinhart Director
Jack V. Talley Director, Executive
Sergio Traversa Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
501 Fifth Avenue 3 Rd Floor
New York, NY, 10017